Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dipeptidyl Peptidase-4 (DPP-4), also known as CD26, is a serine exopeptidase that cleaves dipeptides from the N-terminal end of polypeptides. It plays a crucial role in glucose metabolism by degrading incretin hormones like GLP-1 and GIP. DPP-4 is also involved in immune regulation and other physiological processes. It is a therapeutic target for type 2 diabetes, with DPP-4 inhibitors being used to enhance insulin secretion.
DPP-4 inhibitors block the degradation of incretin hormones (GLP-1 and GIP), leading to increased insulin secretion and reduced glucagon secretion in a glucose-dependent manner.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dipeptidyl Peptidase-4 (DPP-4).